We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 240

Application for an order of prohibition dismissed for formulation patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 18 2015

The Court found that Mylan’s allegations of non-infringement and obviousness were justified. As a result, the application for prohibition was

Court of Appeal upholds decision relating to sildenafil use patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 27 2014

Pfizer Ireland Pharmaceuticals v. Apotex Inc., 2014 FCA 13 Drug: VIAGRA sildenafil In Apotex' action for impeachment of the Pfizer patent

Definition of “innovative drug” does not include variations

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 23 2013

This is an appeal by Takeda of a decision of the Court, in which the Court upheld the decision of the Minister of Health to refuse to list Takeda’s

Pleadings amendments refused on the eve of trial

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 7 2011

BMS brought a motion to strike out certain amendments made to its pleadings by Apotex

Motions judge dismisses appeal from prothonotary on motion to compel

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 28 2011

In the underlying case, Apotex has sued to impeach sanofi’s patent and sanofi and BMS have sued Apotex for infringement

Order of prohibition granted with respect to prodrug of known compound

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 25 2011

The two issues raised in this prohibition proceeding related to whether the claimed compound’s utility was demonstrated or soundly predicted, and whether the claimed compound was obvious

Disgorgement of profits allegation struck when tied to NOC regulations

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 4 2012

This decision relates to two appeals heard together but not consolidated

Pharmacies not permitted to sell “private label” generic drugs

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 4 2012

The Government of Ontario appealed from two Orders of the Divisional Court declaring that sections of provincial regulations banning pharmacies from selling “private label” generic drugs are ultra vires and of no force and effect

Court dismisses NOC proceeding for mootness when NOA withdrawn

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 30 2013

Lilly brought an application for prohibition pursuant to the Patented Medicines (Notice of Compliance) Regulations. Subsequently, Teva established to

Formulation patent allegations of non-infringement, obviousness and lack of utility justified

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 2 2015

Servier sought a prohibition order against Apotex in relation to its DIAMICRON MR gliclazide product. The application was dismissed. The patent at